[go: up one dir, main page]

MX419566B - Inmunglobulinas conjugadas con lisina - Google Patents

Inmunglobulinas conjugadas con lisina

Info

Publication number
MX419566B
MX419566B MX2018015331A MX2018015331A MX419566B MX 419566 B MX419566 B MX 419566B MX 2018015331 A MX2018015331 A MX 2018015331A MX 2018015331 A MX2018015331 A MX 2018015331A MX 419566 B MX419566 B MX 419566B
Authority
MX
Mexico
Prior art keywords
conjugated
immunglobulins
lysine
conjugated immunoglobulins
methods
Prior art date
Application number
MX2018015331A
Other languages
English (en)
Other versions
MX2018015331A (es
Inventor
Earl Albone
Jared Spidel
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59315675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX419566(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2018015331A publication Critical patent/MX2018015331A/es
Publication of MX419566B publication Critical patent/MX419566B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Inmunoglobulinas conjugadas y métodos para generar inmunoglobulinas conjugadas usando una transglutaminasa microbiana.
MX2018015331A 2016-06-10 2017-06-12 Inmunglobulinas conjugadas con lisina MX419566B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662348410P 2016-06-10 2016-06-10
PCT/JP2017/021672 WO2017213267A1 (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Publications (2)

Publication Number Publication Date
MX2018015331A MX2018015331A (es) 2019-08-16
MX419566B true MX419566B (es) 2025-01-14

Family

ID=59315675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015331A MX419566B (es) 2016-06-10 2017-06-12 Inmunglobulinas conjugadas con lisina

Country Status (21)

Country Link
US (2) US10941431B2 (es)
EP (1) EP3468614A1 (es)
JP (1) JP7041077B2 (es)
KR (1) KR102538866B1 (es)
CN (1) CN109475642B (es)
AU (1) AU2017279352B2 (es)
BR (1) BR112018075253A2 (es)
CA (1) CA3026991A1 (es)
CL (1) CL2021003383A1 (es)
CO (1) CO2018013314A2 (es)
IL (1) IL263329B (es)
JO (1) JOP20180118A1 (es)
MX (1) MX419566B (es)
MY (1) MY202858A (es)
NZ (1) NZ748605A (es)
PE (1) PE20190340A1 (es)
PH (1) PH12018502594A1 (es)
RU (2) RU2021136863A (es)
SG (1) SG11201810470XA (es)
UA (1) UA126799C2 (es)
WO (1) WO2017213267A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018012388A2 (pt) 2015-12-18 2018-12-04 Eisai R&D Management Co., Ltd. imunoglobulinas conjugadas de lisina terminal-c
JP7041077B2 (ja) 2016-06-10 2022-03-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 リジン結合体化免疫グロブリン
AR118898A1 (es) * 2019-05-09 2021-11-10 Merus Nv Dominios variantes para multimerizar proteínas y su separación
GB201907093D0 (en) * 2019-05-20 2019-07-03 Ucl Business Plc Antibody functionalisation
JP7399305B2 (ja) * 2020-02-12 2023-12-15 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化
CA3173162A1 (en) * 2020-03-25 2021-09-30 Eli Lilly And Company Multispecific binding proteins and methods of developing the same
JP7787101B2 (ja) 2020-05-20 2025-12-16 ヤンセン バイオテツク，インコーポレーテツド グリコシル化Ｆｃドメインを含むタンパク質の部位特異的コンジュゲーションのための方法
KR20230074517A (ko) * 2020-09-25 2023-05-30 에피백스, 인크. 레트로-인버소 조절 t 세포 에피토프
MX2024002476A (es) * 2021-08-27 2024-05-20 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos.
CN115947830B (zh) * 2022-12-27 2023-09-12 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
AU2024227808A1 (en) 2023-02-28 2025-07-31 Eisai R&D Management Co., Ltd. Anti-psma antibodies, conjugates, and methods of use
EP4687993A2 (en) * 2023-04-07 2026-02-11 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
WO2025020905A1 (zh) * 2023-07-26 2025-01-30 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
ES2397241T3 (es) * 2004-01-21 2013-03-05 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
US9676871B2 (en) * 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013176516A1 (ko) 2012-05-24 2013-11-28 한화케미칼 주식회사 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도
EP3564259A3 (en) * 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014202775A1 (en) * 2013-06-21 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
AU2014286990A1 (en) * 2013-07-11 2016-02-11 Novartis Ag Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
CA2919583C (en) * 2013-07-31 2018-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates
SI3134127T1 (sl) * 2014-04-25 2020-06-30 Rinat Neuroscience Corp. Konjugati zdravil s protitelesi z visoko stopnjo zdravila
BR112018012388A2 (pt) 2015-12-18 2018-12-04 Eisai R&D Management Co., Ltd. imunoglobulinas conjugadas de lisina terminal-c
JP7041077B2 (ja) 2016-06-10 2022-03-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 リジン結合体化免疫グロブリン

Also Published As

Publication number Publication date
JOP20180118A1 (ar) 2019-01-30
EP3468614A1 (en) 2019-04-17
US10941431B2 (en) 2021-03-09
WO2017213267A1 (en) 2017-12-14
AU2017279352A1 (en) 2018-12-13
RU2018145507A3 (es) 2020-10-15
RU2018145507A (ru) 2020-07-10
CO2018013314A2 (es) 2019-02-19
KR102538866B1 (ko) 2023-06-02
RU2021136863A (ru) 2022-02-01
JP7041077B2 (ja) 2022-03-23
IL263329B (en) 2022-05-01
NZ748605A (en) 2023-05-26
CN109475642A (zh) 2019-03-15
SG11201810470XA (en) 2018-12-28
KR20190018159A (ko) 2019-02-21
PH12018502594A1 (en) 2019-10-14
PE20190340A1 (es) 2019-03-07
UA126799C2 (uk) 2023-02-08
US20210171998A1 (en) 2021-06-10
CA3026991A1 (en) 2017-12-14
IL263329A (en) 2018-12-31
JP2019525897A (ja) 2019-09-12
CL2021003383A1 (es) 2022-08-19
BR112018075253A2 (pt) 2019-04-30
MX2018015331A (es) 2019-08-16
MY202858A (en) 2024-05-25
RU2762939C2 (ru) 2021-12-24
AU2017279352B2 (en) 2024-07-25
US11753669B2 (en) 2023-09-12
CN109475642B (zh) 2023-05-02
US20180044711A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
MX419566B (es) Inmunglobulinas conjugadas con lisina
PH12018501272A1 (en) C-terminal lysine conjugated immunoglobulins
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
MX2025006134A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CL2020000596S1 (es) Auriculares.
CL2019001554S1 (es) Automóvil.
BR112018003339A8 (pt) Anticorpos antimesotelina completamente humanos e células imunoefetoras que direcionam mesotelina
SG11202007109QA (en) Generating natural language recommendations based on an industrial language model
MA45231A (fr) Anticorps anti-ige
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
CU20160118A7 (es) Moléculas de anticuerpo que se unen a tim-3
EP3411382A4 (en) Anti-egfr antibody drug conjugate
PL3443130T3 (pl) Inokulant do żeliwa szarego
EP4069008C0 (en) AEROSOL GENERATING DEVICE WITH PIERCING ASSEMBLY
JOP20200056A1 (ar) تركيب غلاية
EP4069009C0 (en) AEROSOL GENERATING DEVICE WITH PIERCING ASSEMBLY
CL2018003506A1 (es) Inmunglobulinas conjugadas con lisina.
CL2019003218S1 (es) Descorchador.
CL2019000140S1 (es) Automóvil.
CL2019000079S1 (es) Estufa.
CL2019000555S1 (es) Licuadora.
AU366483S (en) Street furniture - bench seat
AU367315S (en) Pool
TH1401007155A (th) เครื่องกำเนิดแรงดึงเชิงเส้นที่ใช้กับเซลล์เพาะเลี้ยง